Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $7.3 million.

  • Zenas BioPharma's Share-based Compensation rose 15803.73% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 27551.46%. This contributed to the annual value of $10.8 million for FY2024, which is 20961.37% up from last year.
  • Latest data reveals that Zenas BioPharma reported Share-based Compensation of $7.3 million as of Q3 2025, which was up 15803.73% from $6.0 million recorded in Q2 2025.
  • Zenas BioPharma's Share-based Compensation's 5-year high stood at $7.3 million during Q3 2025, with a 5-year trough of $947000.0 in Q1 2024.
  • In the last 3 years, Zenas BioPharma's Share-based Compensation had a median value of $2.8 million in 2024 and averaged $3.5 million.
  • The largest annual percentage gain for Zenas BioPharma's Share-based Compensation in the last 5 years was 46874.34% (2025), contrasted with its biggest fall of 15803.73% (2025).
  • Over the past 3 years, Zenas BioPharma's Share-based Compensation (Quarter) stood at $1.1 million in 2023, then soared by 384.14% to $5.5 million in 2024, then surged by 33.5% to $7.3 million in 2025.
  • Its Share-based Compensation stands at $7.3 million for Q3 2025, versus $6.0 million for Q2 2025 and $5.4 million for Q1 2025.